Pachyonychia Congenita
No Results
No Results
processing….
Pachyonychia congenita is a rare genodermatosis due to mutations in one of four keratin genes. It is characterized by dystrophic, thickened nails and painful palmoplantar keratoderma. Müller made one of the first documented observations of pachyonychia congenita in 1904.{ref1-INVALID REFERENCE} The next reports were published in 1905 by Wilson [1] and in 1906 by Jadassohn and Lewandowsky. [2]
Based on available case reports and small series, the disorder has historically been divided into 2 main subtypes. Pachyonychia congenita type 1, or the Jadassohn-Lewandowsky type (Mendelian Inheritance in Man (MIM entry 167200), was attributed to mutations in genes encoding keratin 6A (KRT6A) or keratin 16 (KRT16) and constituted the most common form of the disorder. [3] Pachyonychia congenita type 2, or the Jackson-Lawler type (MIM entry 167210), was attributed to mutations in keratin 6B (KRT6B) or keratin 17 (KRT17) and could be distinguished from type 1 by the development of natal teeth, widespread steatocystomas, and occasionally pili torti.
Recent large phenotype-genotype studies of patients from the International Pachyonychia Congenita Research Registry (IPCRR) [4, 5] have provided a clearer picture of the disease and reveal a spectrum of overlapping clinical features that can be correlated genotypically to the specific mutations in patients with pachyonychia congenita.
Keratins are key structural proteins that form the cytoskeleton of epithelial cells. They are classified based on their biochemical properties into either type I (K9-K28, K31-K40) or type II keratins (K1-K8, K71-K86). Keratin intermediate filament assembly begins with the pairing of a type I keratin protein and type II keratin protein to form an alpha helical heterodimer. Two heterodimers then form a tetramer. The tetramers subsequently aggregate to form larger order polymers that give rise to a keratin intermediate filament.
Fifty four different keratin genes have been identified. Various epithelial cell types express a different range of keratins based on cell function. The mutations in pachyonychia congenita are found in the genes encoding keratin 6A (KRT6A), keratin 16 (KRT16), keratin 6B (KRT6B), and keratin 17 (KRT17). [6, 7, 8] Keratin 6A partners with keratin 16 whereas keratin 6B partners with keratin 17. These keratins are constitutively expressed in keratinocytes of the nail, palmoplantar skin, mucosa, and hair, leading to the manifestations of the disorder in these sites.
The basic protein structure of a keratin filament consists of an alpha-helical rod that is divided into 4 domains (1A, 1B, 2A, 2B) connected together by nonhelical linkers (L1, L12, L2). A helix initiation motif and a helix termination motif segment can be found at either end of the alpha-helical rod and are highly conserved in sequence between keratins. As with most other keratin disorders, most mutations in pachyonychia congenita occur in these highly conserved helix boundary domains at the end of the rod domain. Proper function of these highly conserved domains appears to be critical for normal keratin filament assembly and cytoskeletal integrity; mutations result in cell fragility.
Although the exact frequency of pachyonychia congenita is unknown, it appears to be rare. An estimated 5,000–10,000 cases have been reported worldwide. [9]
Pachyonychia congenita affects both sexes equally. [4, 10]
Patients with pachyonychia congenita often present at birth or soon after with the characteristic hypertrophic toenail dystrophy. [4]
Pachyonychia congenita is not associated with a reduced lifespan.
Patients and their relatives should be informed that pachyonychia congenita does not endanger an individual’s life, but it may impair his or her quality of life. The patient may be informed that at present, no effective treatment is available; however, gene therapy treatment may become available in the future. A genetic counselor should inform the carrier that this gene has an autosomal dominant inheritance pattern and that pachyonychia congenita can affect half of his or her progeny.
Wilson AG. Three cases of hereditary hyperkeratosis of the nail bed. Br J Dermatol. 1905. 17:13-14.
Jadassohn J, Lewandowsky F. Pachyonychia congenita. Keratosis disseminata circumscripta (follicularis). Tylomata. Leukokeratosis linguae. Jacob’s Ikonographia Dermatologica. Berlin: Urban und Schwarzenberg; 1906. 1: 29-30.
McKusick V. Mendelian Inheritance in Man. 11th ed. Baltimore: J Hopkins University Press; 1994.
Eliason MJ, Leachman SA, Feng BJ, Schwartz ME, Hansen CD. A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol. 2012 Jan 18. [Medline].
Shah S, Boen M, Kenner-Bell B, Schwartz M, Rademaker A, Paller AS. Pachyonychia congenita in pediatric patients: natural history, features, and impact. JAMA Dermatol. 2014 Feb 1. 150(2):146-53. [Medline].
Liao H, Sayers JM, Wilson NJ, Irvine AD, Mellerio JE, Baselga E. A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita. J Dermatol Sci. 2007 Dec. 48(3):199-205. [Medline].
Terrinoni A, Smith FJ, Didona B, et al. Novel and recurrent mutations in the genes encoding keratins K6a, K16 and K17 in 13 cases of pachyonychia congenita. J Invest Dermatol. 2001 Dec. 117(6):1391-6. [Medline].
Smith FJ, Liao H, Cassidy AJ, et al. The genetic basis of pachyonychia congenita. J Investig Dermatol Symp Proc. 2005 Oct. 10(1):21-30. [Medline].
Kaspar RL. Challenges in developing therapies for rare diseases including pachyonychia congenita. J Investig Dermatol Symp Proc. 2005 Oct. 10(1):62-6. [Medline].
Smith FJD, Kaspar RL, Schwartz ME, McLean WHI, Leachman SA. Pachyonychia Congenita. 1993. [Medline].
Leachman SA, Kaspar RL, Fleckman P, et al. Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc. 2005 Oct. 10(1):3-17. [Medline].
Wallis T, Poole CD, Hoggart B. Can skin disease cause neuropathic pain? A study in pachyonychia congenita. Clin Exp Dermatol. 2016 Jan. 41(1):26-33. [Medline].
Brill S, Sprecher E, Smith FJD, Geva N, Gruener H, Nahman-Averbuch H, et al. Chronic pain in pachyonychia congenita: evidence for neuropathic origin. Br J Dermatol. 2018 Jul. 179 (1):154-162. [Medline].
Feinstein A, Friedman J, Schewach-Millet M. Pachyonychia congenita. J Am Acad Dermatol. 1988 Oct. 19(4):705-11. [Medline].
Munro CS. Pachyonychia congenita: mutations and clinical presentations. Br J Dermatol. 2001 May. 144(5):929-30. [Medline].
Moon SE, Lee YS, Youn JI. Eruptive vellus hair cyst and steatocystoma multiplex in a patient with pachyonychia congenita. J Am Acad Dermatol. 1994 Feb. 30(2 Pt 1):275-6. [Medline].
Clementi M, Cardin de Stefani E, Dei Rossi C, Avventi V, Tenconi R. Pachyonychia congenita Jackson-Lawler type: a distinct malformation syndrome. Br J Dermatol. 1986 Mar. 114(3):367-70. [Medline].
Su WP, Chun SI, Hammond DE, Gordon H. Pachyonychia congenita: a clinical study of 12 cases and review of the literature. Pediatr Dermatol. 1990 Mar. 7(1):33-8. [Medline].
Wollina U, Schaarschmidt H, Fünfstück V, Knopf B. Pachyonychia congenita. Immunohistologic findings. Zentralbl Pathol. 1991. 137(4):372-5. [Medline].
Milstone LM, Fleckman P, Leachman SA, et al. Treatment of pachyonychia congenita. J Investig Dermatol Symp Proc. 2005 Oct. 10(1):18-20. [Medline].
Tidman MJ, Wells RS. Control of plantar blisters in pachyonychia congenita with topical aluminium chloride. Br J Dermatol. 1988 Mar. 118(3):451-2. [Medline].
Swartling C, Vahlquist A. Treatment of pachyonychia congenita with plantar injections of botulinum toxin. Br J Dermatol. 2006 Apr. 154(4):763-5. [Medline].
González-Ramos J, Sendagorta-Cudós E, González-López G, Mayor-Ibarguren A, Feltes-Ochoa R, Herranz-Pinto P. Efficacy of botulinum toxin in pachyonychia congenita type 1: report of two new cases. Dermatol Ther. 2016 Jan. 29 (1):32-6. [Medline].
Thomas DR, Jorizzo JL, Brysk MM, Tschen JA, Miller J, Tschen EH. Pachyonychia congenita. Electron microscopic and epidermal glycoprotein assessment before and during isotretinoin treatment. Arch Dermatol. 1984 Nov. 120(11):1475-9. [Medline].
Dupre A, Christol B, Bonafe JL, Touron P. [Pachyonychia congenita. Three familial cases. Effects of the treatment by aromatic retinoid (RO 10.9359) (author’s transl)]. Ann Dermatol Venereol. 1981. 108(2):145-9. [Medline].
Hickerson RP, Leake D, Pho LN, Leachman SA, Kaspar RL. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J Dermatol Sci. 2009 Nov. 56(2):82-8. [Medline].
U.S. Food and Drug Administration (FDA). Orphan Drug Designations and Approvals. Sirolimus; treatment of pachyonychia congenita. Available at http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=391013. Accessed: January 24, 2014.
Teng JMC, Bartholomew FB, Patel V, Sun G. Novel treatment of painful plantar keratoderma in pachyonychia congenita using topical sirolimus. Clin Exp Dermatol. 2018 Dec. 43 (8):968-971. [Medline].
Zhao Y, Gartner U, Smith FJ, McLean WH. Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. J Invest Dermatol. 2011 May. 131 (5):1045-52. [Medline].
Abdollahimajd F, Rajabi F, Shahidi-Dadras M, Saket S, Youssefian L, Vahidnezhad H, et al. Pachyonychia congenita: a case report of a successful treatment with rosuvastatin in a patient with a KRT6A mutation. Br J Dermatol. 2018 Oct 11. [Medline].
Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010 Feb. 18(2):442-6. [Medline]. [Full Text].
Trochet D, Prudhon B, Vassilopoulos S, Bitoun M. Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfalls. Curr Gene Ther. 2015. 15 (5):503-10. [Medline].
Thomsen RJ, Zuehlke RL, Beckman BI. Pachyonychia congenita: surgical management of the nail changes. J Dermatol Surg Oncol. 1982 Jan. 8(1):24-8. [Medline].
GARB J. Pachyonychia congenita; regression of plantar lesions on patients wearing specially made rubber base foot molds and shoes. Arch Derm Syphilol. 1950 Jul. 62(1):117-24. [Medline].
Saira J George, MD Assistant Professor, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center
Saira J George, MD is a member of the following medical societies: American Academy of Dermatology, Houston Dermatological Society
Disclosure: Nothing to disclose.
David F Butler, MD Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society for MOHS Surgery, Association of Military Dermatologists, Phi Beta Kappa
Disclosure: Nothing to disclose.
Lester F Libow, MD Dermatopathologist, South Texas Dermatopathology Laboratory
Lester F Libow, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, Texas Medical Association
Disclosure: Nothing to disclose.
William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine
William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology
Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.
Gregory J Raugi, MD, PhD Professor, Department of Internal Medicine, Division of Dermatology, University of Washington at Seattle School of Medicine; Chief, Dermatology Section, Primary and Specialty Care Service, Veterans Administration Medical Center of Seattle
Gregory J Raugi, MD, PhD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.
The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Aleksej Kansky, MD, PhD, to the development and writing of this article.
Pachyonychia Congenita
Research & References of Pachyonychia Congenita|A&C Accounting And Tax Services
Source
0 Comments